Citizens reiterates Rezolute stock rating on tumor trial results due

Citizens has reaffirmed a bullish Market Outperform rating and a $11.00 price target for Rezolute (NASDAQ: RZLT) following the presentation of promising tumor-associated hyperinsulinism trial results. The company anticipates delivering top-line revenue from its Phase 3 upLIFT trial, which assesses the efficacy of ersodetug in treating this condition, by the end of 2026.

Despite currently trading 66% below its 52-week peak of $11.46, Rezolute's stock has surged 67% year-to-date, with analyst price targets spanning from $4 to $14. The company disclosed fiscal fourth quarter 2026 results and strategic updates, maintaining substantial cash reserves of approximately $108 million, bolstering its ability to complete the tumor-associated hyperinsulinism clinical trials.

Citizens' financial health metrics also reveal a robust liquidity position, with a current ratio of 9.68 and more cash than debt on the balance sheet. This favorable outlook stems from a risk-adjusted discounted cash flow model employed by Citizens. Recent discussions with Rezolute's Chief Medical Officer, Dr. Brian Roberts, further emphasize the company's ongoing projects, including positive findings from the open-label extension of their studies and the durability observed in objective tumor-HI responses.

These updates come in the wake of the Phase 3 sunRIZE trial, which did not achieve its primary objective, and precede the conclusive upLIFT readout, capturing the attention of investors who will closely monitor these developments.